Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)-triene-3,20-dione Monomethane Sulfonate
2. Freedox
3. Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16alpha)-, Monomethanesulfonate
4. Tirilazad Mesylate
5. Tirilazad Mesylate Hydrate
6. U 74006f
7. U-74006
8. U-74006f
9. U74006f
1. 110101-66-1
2. Tirilazadmesylate
3. U 74006
4. Pnu 74006f
5. Tirilazad (inn)
6. Yd064e883i
7. U-74006
8. (8s,10s,13s,14s,16r,17s)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
9. Tirilazad [inn]
10. Tirilazadum
11. Tirilazad [inn:ban]
12. Tirilazadum [inn-latin]
13. Unii-yd064e883i
14. Butamiratecitrate
15. Tirilazad [mi]
16. Tirilazad [vandf]
17. Tirilazad [who-dd]
18. Schembl483318
19. Chembl1630578
20. Dtxsid30869521
21. Chebi:135853
22. Zinc43133316
23. Db13050
24. Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)erazinyl)-16-methyl-, (16alpha)-
25. Hy-132280
26. Cs-0182791
27. D08606
28. Q7809222
29. 16alpha-methyl-21-[4[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione
30. 16alpha-methyl-21-[4[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1piperazinyl]pregna-1,4,9(11)-triene-3,20-dione
31. 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione
32. Pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16.alpha.)-
| Molecular Weight | 624.9 g/mol |
|---|---|
| Molecular Formula | C38H52N6O2 |
| XLogP3 | 5.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 624.41517492 g/mol |
| Monoisotopic Mass | 624.41517492 g/mol |
| Topological Polar Surface Area | 72.9 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 1290 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Neuroprotective Agents
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. (See all compounds classified as Neuroprotective Agents.)
N - Nervous system
N07 - Other nervous system drugs
N07X - Other nervous system drugs
N07XX - Other nervous system drugs
N07XX01 - Tirilazad
Tirilazad has known human metabolites that include (8S,10R,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, 17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, 17-[2-[4-[2-(3-hydroxypyrrolidin-1-yl)-6-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, and 17-[2-[4-[6-(3-hydroxypyrrolidin-1-yl)-2-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
ABOUT THIS PAGE
A Tirilazad manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tirilazad, including repackagers and relabelers. The FDA regulates Tirilazad manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tirilazad API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Tirilazad supplier is an individual or a company that provides Tirilazad active pharmaceutical ingredient (API) or Tirilazad finished formulations upon request. The Tirilazad suppliers may include Tirilazad API manufacturers, exporters, distributors and traders.
click here to find a list of Tirilazad suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tirilazad CEP of the European Pharmacopoeia monograph is often referred to as a Tirilazad Certificate of Suitability (COS). The purpose of a Tirilazad CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tirilazad EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tirilazad to their clients by showing that a Tirilazad CEP has been issued for it. The manufacturer submits a Tirilazad CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tirilazad CEP holder for the record. Additionally, the data presented in the Tirilazad CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tirilazad DMF.
A Tirilazad CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tirilazad CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tirilazad suppliers with CEP (COS) on PharmaCompass.
Tirilazad Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tirilazad GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tirilazad GMP manufacturer or Tirilazad GMP API supplier for your needs.
A Tirilazad CoA (Certificate of Analysis) is a formal document that attests to Tirilazad's compliance with Tirilazad specifications and serves as a tool for batch-level quality control.
Tirilazad CoA mostly includes findings from lab analyses of a specific batch. For each Tirilazad CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tirilazad may be tested according to a variety of international standards, such as European Pharmacopoeia (Tirilazad EP), Tirilazad JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tirilazad USP).
LOOKING FOR A SUPPLIER?
